Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694158 · ClinicalTrials.gov registry record · Phase 4
Investigating Dupilumab's Effect in Asthma by Genotype
A Phase 4 study of Asthma, sponsored by Boston Children's Hospital.
- Active
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 6
- Study locations
NCT03694158 is a Phase 4 study of Asthma that is active but no longer recruiting, run by Boston Children's Hospital. The registered enrollment target is 150 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT03694158, a Phase 4 study of Asthma, is active but no longer recruiting, sponsored by Boston Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 6
- Study locations
Study Summary
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma exacerbations.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dupilumab
Study Locations (6)
Massachusetts
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
Michigan
- Henry Ford Health System - Detroit
New York
- Montefiore Einstein Clinical Research Center - The Bronx
Ohio
- MetroHealth System - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2027-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694158
The ClinicalTrials.gov registry entry for NCT03694158 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (90% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03694158 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT03694158 about?
NCT03694158 is a clinical study titled "Investigating Dupilumab's Effect in Asthma by Genotype". The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma e...
What is the current status of trial NCT03694158?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2021-09-08. Estimated completion is 2027-03.
What conditions does trial NCT03694158 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT03694158?
The interventions under investigation include: Placebo (OTHER), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03694158?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03694158 being conducted?
This trial has 6 study locations across Massachusetts, Michigan, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.